55 results about "Virosome" patented technology

The invention discloses a method for quickly rescuing bovine coronavirus epidemic strains and application of the method. The bovine coronavirus SHZ isolate is subjected to efficient segmented cloning, the obtained segment and a Linker sequence are subjected to a cyclic polymerase extension reaction, and the obtained reaction product can be directly transfected to 293T cells for virus packaging without purification. Different from a traditional method, the method does not need to amplify full-length virus cDNA clone by means of bacteria and yeast, but directly obtains a sufficient amount of preliminary products through PCR, and avoids the problems of instability and low efficiency when partial sequences of a virus genome proliferate in a bacteria or yeast host. By adopting the reverse genetic system, the recombinant bovine coronavirus expressing the foreign protein is successfully rescued, a brand new technical platform is provided for dynamic visualization research of in-vivo and in-vitro replication of the virus, and an efficient and flexible tool is also provided for virology research, development of virus vector vaccines and screening of antiviral drugs.

The invention provides a cell strain for producing engineered viroid particles, a method thereof and the engineered viroid particles, the cell strain is named as SZCV-Con28 and preserved in Guangdong Microbial Culture Collection Center on October 15, 2025, the preservation number is GDMCC No: 67101, and the preservation number is GDMCC No: 67101. A plurality of corresponding cell factories for producing the engineered viroid particles are established by cell lines obtained by introducing different target gRNA elements into the cell strain, so that the corresponding engineered viroid particles can be continuously produced in batches. According to the invention, large-scale preparation can be realized through cell expanding culture, the capacity limitation is overcome, the production process flow is simplified, and the consumption of production raw materials is reduced.

The present disclosure provides recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein. In particular, the disclosure provides AAV9 virions with engineered AAV9 capsid, AAV5 / 9 chimeric capsid or combinatory capsid that achieves increased transduction efficiency in cardiac cells, increased cell-type selectivity, and / or other desirable properties.

Polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods for expressing AAV Rep proteins are provided. In certain aspects, among the provided embodiments are polynucleotides, vectors, and systems of vectors or polynucleotides, and cells including the same, that include a polynucleotide that includes a ribozyme. In certain aspects, these polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods may be used to produce higher levels of small Rep transcripts as compared to large Rep transcripts. In certain aspects, these polynucleotides, vector systems, cells, and methods may be used to produce higher levels of small Rep proteins as compared to large Rep proteins. In certain aspects, these polynucleotides, vectors, vector systems, cells, and methods may be used to produce recombinant AAV (rAAV). Increased expression of small Rep as compared to large Rep is useful in many aspects, such as, increasing total virions and increasing packaged virions during the production of rAAV.

The embodiment of the application discloses a virus structure three-dimensional reconstruction method and system, the method comprises the following steps: acquiring stereoscopic data and point cloud data containing a target virus sample; separating virus particles from the point cloud data by using an optimized point cloud segmentation algorithm; separating virus regions from the stereoscopic data by using a stereoscopic data segmentation algorithm; processing the virus stereoscopic data by using a first neural network to obtain density characteristics of the virus structure; processing the virus point cloud by using a second neural network to obtain geometric characteristics of the virus surface; fusing the density characteristics and the geometric characteristics by using a multi-modal fusion model to generate unified feature representation; and reconstructing a three-dimensional model of the virus structure based on the unified feature representation. The application can accurately obtain the three-dimensional structure of the virus in a complex background, and improves the accuracy of virus three-dimensional reconstruction.

Immunization with nucleic acids is achieved by delivering a self-replicating RNA encapsulated in a small particle. The RNA encodes an immunogen of interest, and the particle can deliver the RNA by mimicking the delivery function of a natural RNA virus. Accordingly, the invention provides a particle other than a virion for in vivo delivery of RNA to a vertebrate cell, wherein the particle comprises a delivery material that encapsulates a self-replicating RNA molecule encoding an immunogen. Such particles are useful as components of pharmaceutical compositions for immunizing subjects against various diseases.

The present disclosure provides nucleic acid constructs (e.g., HDAd vectors), set of nucleic acid constructs (e.g., one or more HDAd vectors), HDAd virions, and HDAd virus comprising all the components for site-specifically integrating an exogenous nucleic acid into a cellular genome at a desired target sequence. The present disclosure also provides methods of using the same.

Described herein are polynucleotide constructs for inducible production of rAAV virions. Also provided are stable cell lines for inducible expression of rAAV virions that include a payload polynucleotide.

The present invention provides a recombinant adeno-associated virus (rAAV) virion comprising a variant capsid polypeptide, wherein the variant capsid polypeptide comprises an alteration to an amino acid corresponding to an adeno-associated virus (AAV) capsid polypeptide amino acid selected from the list consisting of any one or more of V125, V183, N411, Y447, R490, T495 and F536 of SEQ ID NO:1; and the variant capsid polypeptide comprises an alteration to increase retrograde transport of the rAAV virion by neuronal axons.

The application discloses application of Punicalin in preparation of a medicine for resisting respiratory syncytial virus. The respiratory syncytial virus is an RNA virus, and is the most important virus body causing acute lower respiratory tract infection of children under 5 years old in the world. It is found that the Punicalin can effectively inhibit replication of the respiratory syncytial virus and effectively resist respiratory syncytial virus infection. Therefore, the Punicalin has the prospect of being developed into the medicine for resisting the respiratory syncytial virus.

Provided is a variant AAV capsid protein, comprising one or more modifications. The modification comprises an insertion of amino acid sequences selected from the group consisting of SEQ ID NOs: 1-10091, and SEQ ID NOs: 20202-35556, or a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-10091, and SEQ ID NOs: 20202-35556. A polynucleotide, a host cell, a vector, an AAV virion and a pharmaceutical composition thereof are also provided. Further provided is a method of treating disease. The method comprises administering to a subject in need thereof an effective amount of the recombinant AAV virion.

The set of inventions relates to biotechnology and medicine, and more particularly to expression vectors for producing proteins in mammalian cells, combinations of said expression vectors for the treatment of congenital adrenal hyperplasia and methods contemplating the use of said combinations, and sets of expression vectors based on adeno-associated virus (AAV) virions, it is useful for medical use, and in particular for the treatment of congenital adrenal hyperplasia.

This invention relates to novel surface modified viral capsids and recombinant virions comprising the same. Furthermore, this invention concerns intermediates for the preparation of surface modified viral capsids. The surface modified viral capsids are designed to selectively and / or more efficiently deliver gene therapy. The surface modified viral capsids, when incorporated into a recombinant virion, can be used to treat an illness that is characterized by genetic abnormality.

The invention discloses an anti-HPV (human papillomavirus) underwear laundry detergent based on a sulfated polysaccharide compound system, which is prepared from the following raw materials in percentage by mass: 0.3 to 2 percent of sodium citrate, 6 to 12 percent of fatty alcohol polyoxyethylene ether sodium sulfate, 4 to 10 percent of fatty alcohol polyoxyethylene ether sodium sulfosuccinate, 1.5 to 5 percent of cocamidopropyl betaine, 2 to 6 percent of lauramide propyl hydroxy sulfobetaine and the balance of water. The cleaning agent is prepared from the following components in percentage by weight: 2 to 8 percent of alkyl glycoside, 2 to 6 percent of potash soap, 0.1 to 0.3 percent of citric acid, 0.2 to 0.5 percent of protease, 0.8 to 2.5 percent of sulfated polysaccharide, 0.2 to 0.5 percent of silver ion, 0.2 to 0.6 percent of dichloro, 0.1 to 0.2 percent of Kathon, 0.2 to 0.5 percent of essence, 0.5 to 1.5 percent of sodium chloride and the balance of deionized water. According to the invention, a brand-new ternary synergistic antiviral system composed of sulfated polysaccharide, silver ions and diclosan is creatively constructed, and the inactivation rate of the system to pseudoviruses HPV-16 and HPV-18 is increased to gt; compared with a binary combination with the optimal effect, the activity of the compound is improved by more than one order of magnitude, and the qualitative change from partial inhibition to complete removal is realized. The efficient cleaning capacity brought by the synergistic effect can cut off the path of contact transmission of viruses through fabrics such as underwear from the source, and a feasible solution is provided for daily physical prevention of HPV-related infection.

In some aspects, the present disclosure provides engineered adeno-associated virus (AAV) capsid proteins comprising a non-naturally occurring amino acid motif described herein. In some embodiments, the present disclosure provides an AAV9, AAV5, AAVrh.10 or AAVrh.74-based engineered capsid protein, that when assembled into virions, achieves increased transduction efficiency of the heart, and / or other desirable properties. Also provided herein are recombinant AAV virions comprising any of the engineered capsid proteins described herein and uses thereof.

The application belongs to the field of virus bodies. The application provides an AAV capsid protein mutant and application thereof, wherein at least one of QNDIKNG, GNDLRPT, NGNAIVG and DNNLAKL is inserted between any two amino acids of a surface variable region of a VP1 protein of a wild type or modified AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh.74 and AAVrh.10 or a protein having at least 80% sequence identity with the amino acid sequence of the above proteins. Compared with the existing AAV capsid protein, the insertion of the amino acid sequence of the AAV capsid protein mutant of the application causes a significant increase in the transduction efficiency of the adeno-associated virus on peripheral blood-derived macrophages, bone marrow-derived macrophages and microglial cells.

The invention discloses a TAT-recombinant avian beta defensin fusion protein as well as a coding gene and application thereof, and belongs to the technical field of variation or genetic engineering. The TAT and the recombinant avian beta defensin (AvBD) are fused for the first time, the TAT-recombinant avian beta defensin fusion protein is constructed, the efficient cell penetrating ability of the TAT and the antiviral ability of the recombinant avian beta defensin are fused, the inhibition effect on virus infection is remarkably enhanced, and the TAT-recombinant avian beta defensin fusion protein can be used for preparing the recombinant avian beta defensin-TAT-recombinant avian beta defensin fusion protein. The fusion protein shows excellent antiviral activity in an in-vitro cell model and an in-vivo live chicken experiment, and can be applied as an antiviral biological preparation; the cell-penetrating peptide TAT is used for preparing a transmembrane delivery system, intracellular delivery of protein is achieved in one step, in-vitro and in-vivo proliferation of avian viruses such as ALV-J, REV, MDV and CIAV is remarkably inhibited, safety and high efficiency are achieved, the cell-penetrating peptide TAT can be developed into a broad-spectrum antiviral biological agent, and meanwhile a new thought of avian virus prevention and treatment research is created.

The present invention is in the field of virions. The invention provides an AAV capsid protein mutant and application thereof. At least one of oligopeptide amino acid sequences QNDIKNG, GNDLRPT, NGNAIVG and DNNLAKL is inserted between any two amino acids in a surface variable region of at least one of wild type or modified capsid protein VP1 of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh.74 and AAVrh.10 or proteins with at least 80% sequence consistency with the amino acid sequences of the above proteins. Compared with the existing AAV capsid protein, the AAV capsid protein mutant has the advantage that the transduction efficiency of the adeno-associated virus on peripheral blood-derived macrophages, bone marrow-derived macrophages and microglial cells is remarkably improved due to the insertion of the amino acid sequence.

The application discloses a TAT-recombinant avian beta defensin fusion protein and a coding gene and application thereof, and belongs to the technical field of variation or genetic engineering. The application firstly fuses TAT with a recombinant avian beta defensin (AvBD) to construct a TAT-recombinant avian beta defensin fusion protein, the efficient cell penetration ability of TAT is fused with the antiviral ability of the recombinant avian beta defensin, and the inhibiting effect on virus infection is significantly enhanced. The fusion protein shows excellent antiviral activity in an in-vitro cell model and an in-vivo live chicken experiment, and can be applied as an antiviral biological preparation. The application uses a cell-penetrating peptide TAT to prepare a transmembrane delivery system, realizes intracellular delivery of a protein in one step, significantly inhibits in-vitro and in-vivo proliferation of avian viruses such as ALV-J, REV, MDV, CIAV and the like, is safe and efficient, can be developed into a broad-spectrum antiviral biological preparation, and simultaneously creates a new idea for research on prevention and treatment of avian viruses.

The invention relates to recombinant adeno-associated virus (rAAV) virions for gene therapy, wherein the rAAV virions comprise a novel capsid protein. In particular, the invention relates to the use of such virions in gene therapy for the treatment of an arthritic disease, such as for example rheumatoid arthritis, or symptoms thereof, preferably by intraarticular administration.

The present invention discloses, inter alia, novel inhibitory RNAs or polynucleotide sequences encoding inhibitory RNAs, as well as expression cassettes, vectors, virions, synthetic microRNAs, synthetic pre-microRNAs and cells, as well as related medical uses and methods of modulating protein expression, in particular B2M protein expression.

The application relates to the technical field of biology, and aims to provide a zinc ion-containing influenza A virus culture medium and a preparation method. The culture medium contains a serum-free cell culture medium, water and PBS buffer, and 20 g / L of bovine serum albumin with a final concentration, 2 ug / mL of TPCK-Trypsin with a final concentration, and 0.009-0.015 mmol / L of zinc ions with a final concentration. The zinc ions which are originally considered to have a virus inhibiting effect under a lower concentration condition can be used to promote virus replication after the concentration range is adjusted; thus, a brand-new culture medium which can be applied to a common cell model and a virus in-vitro culture model for studying the influenza A virus is provided, and a new solution for optimizing a vaccine production process is provided. The culture medium formula is simple and convenient to prepare; all the raw material components are common consumables in laboratories, the liquid components required can be prepared in advance and stored in cold storage for standby, and the culture medium can support mass vaccine production.

Vectors, cell lines comprising the vectors, recombinant virions produced from the vectors, and methods of using the vectors for barcoding nuclei of cells are provided. Vector libraries that collectively encode a plurality of genetic elements of interest for screening and methods of screening cells having nuclei barcoded according to the subject methods are also provided.

The present invention provides for recombinant adeno-associated virus (rAAV) virions comprising a variant capsid polypeptide, wherein the variant capsid polypeptide comprises an alteration to an amino acid corresponding to an adeno-associated virus (AAV) capsid polypeptide amino acid selected from the list consisting of any one or more of V125, V183, N411, Y447, R490, T495, and F536 of SEQ ID NO: 1; and wherein the variant capsid polypeptide comprises an alteration to increase retrograde transport of the rAAV virion by an axon of a neuron. The present invention also provides for recombinant adeno-associated virus (rAAV) variant capsid polypeptides, wherein the variant capsid polypeptide comprises an alteration to an amino acid corresponding to an adeno-associated virus (AAV) capsid polypeptide amino acid selected from the list consisting of any one or more of V125, V183, N411, Y447, R490, T495, and F536 of SEQ ID NO: 1.

Provided are recombinant adeno-associated virus (rAAV) vectors comprising a transgene to express galactose- 1 -phosphate uridylyl transferase (GALT); virions comprising said vectors (rAAV virions); methods of their production; methods of their use, including methods for treating galactosemia, GALT -deficiency, symptoms therefrom; and kits.

This description relates to oral vaccine dosage forms and processes for producing oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) that contain an immunogenic quantity of at least one vaccine target molecule, with or without an adjuvant. Specifically, the applicants have discovered a combination of the composition of liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and manufacturing conditions for the dosage forms that can produce a lyophilized sublingual dosage form that has physical robustness, particle integrity, and antigen stability.

Provided herein are methods for expression of anti-C3 molecule by administering a recombinant adeno-associated virus (rAAV) virion in an amount capable of blocking C3 activity in the eye.

The invention discloses application of TAT-MSI1 fusion protein in promotion of virus in-vitro proliferation, and belongs to the technical field of virology. The TAT and the RNA binding protein MSI1 are fused for the first time, the TAT-MSI1 fusion protein is constructed, the efficient cell penetrating power of the TAT is combined with the RNA binding protein function of the MSI1, and a brand new tool is provided for studying replication of some viruses difficult to replication; secondly, a transmembrane delivery system is prepared by using the cell-penetrating peptide TAT, so that a technical means is provided for rapidly and greatly obtaining antigens in vaccine production.

The present invention provides a variant AAV capsid protein, comprising a substituted amino acid sequence corresponding to VR I-VR IX region of the amino acid sequence of SEQ ID NO:1, and the polynucleotide, host cells, vectors, AAV virion or the pharmaceutical composition thereof. The present invention further provides a method of treating disease, the method comprising administering to a subject in need thereof an effective amount of the recombinant AAV virion.

The disclosure provides recombinant vaccinia vectors (rVACV) comprising variant A34R proteins. As compared to a vaccinia vector comprising the wild-type A34R protein, the rVACVs described herein exhibit increased production of extra-cellular enveloped virion (EEV). Also described herein are variant A34R proteins, nucleic acids encoding variant A34R proteins, and cells containing the nucleic acids encoding variant A34R proteins. The disclosure further provides methods of producing rVACV by culturing the cells containing the nucleic acids encoding variant A34R proteins and purifying the rVACV. Furthermore, provided are methods of treating a cancer in a subject by administering to the subject rVACVs comprising the variant A34R proteins.